Another Look At Marketing Vs. R&D In Pharma
Derek Lowe
•
Thu, May 23
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
23,010 people get PFE articles and Market Currents by email alert.
Get email alerts on PFE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Another Look At Marketing Vs. R&D In PharmaDerek Lowe • Thu, May 23 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Pfizer's CEO Discusses Q3 2012 Results - Earnings Call TranscriptThu, Nov 1, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, May 1, 2012
-
Pfizer's CEO Hosts 2012 Annual Meeting (Transcript)Thu, Apr 26, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Nov 1, 2011
-
Pfizer's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Aug 2, 2011
-
Pfizer's CEO Discusses Q1 2011 Results - Earnings Call TranscriptTue, May 3, 2011 • 1 Comment
-
Pfizer's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 1, 2011 • 1 Comment
-
Pfizer CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Nov 2, 2010
-
Pfizer Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Pfizer Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Pfizer Inc. Q4 2009 Earnings Call TranscriptWed, Feb 3, 2010
-
Pfizer, Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Pfizer Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
Pfizer Q1 2009 Earnings Call TranscriptTue, Apr 28, 2009
-
Pfizer Q4 2008 Earnings and Conference Call TranscriptWed, Jan 28, 2009
-
at CNBC.com (Wed, 4:08PM)
-
at Fox Business (Wed, 10:13AM)
-
Business Wire (Wed, 8:00AM)
-
at Fox Business (Wed, 7:27AM)
-
at CNBC.com (Tue, 4:07PM)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 10, 2013)
-
Business Wire (May 8, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at Fox Business (May 2, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 30, 2013)
PFE vs. ETF Alternatives
Company Description
Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 22, 11:07 AM AIG remains at the top Goldman's list of hedge fund hotels (the 50 stocks appearing most frequently among hedge fund top 10 holdings). Google (GOOG) retains its #2 position. Apple (APPL) - in the top spot for 3 years until February - remains at #3. Goldman notes the basket has outperformed the S&P a bit this year and the top 20 has done better by more than 1000 basis points. We smell an ETF offering. The rest of the top 20: C, GM, PCLN, VMED, NWSA, MSFT, HTZ, JPM, APC, PFE, QCOM, CHTR, HES, CBS, EBAY, DAL, EQIX. 4 Comments
- Wednesday, May 22, 8:18 AM Pfizer (PFE) plans to spin off its remaining stake in Zoetis (ZTS) through a tax-free exchange offer in which Pfizer owners can exchange their Pfizer shares for stock in Zoetis owned by Pfizer (got that?). Pfizer has received a waiver of the 180-day lock-up from the book runners of the Zoetis IPO. PFE +2.1%, ZTS -1.2% premarket. (PR) 9 Comments [Healthcare, Breaking News, On the Move]
- Monday, May 20, 5:23 PM Pfizer (PFE) says it's discontinuing Phase 3 studies on its investigational compound inotuzumab ozogamicin in combination with rituximab, a treatment for patients with non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy, after the study failed to meet its primary objective of improving overall survival. No new or unexpected safety issues were identified, and PFE says it's continuing to review the the drug for potential subset applications. Shares -0.3% AH. Comment! [Healthcare]
- Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
- Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
- Monday, May 6, 9:38 AM More on Pfizer (PFE -0.5%): A plan by the company to sell Viagra online is motivated by the estimated hundreds of millions of dollars it loses to counterfeit versions of the drug found online. A ticking clock for patent expiration (2020) in the U.S. could also be a factor. To attract new customers, Pfizer will reportedly become more promotional with Viagra by offering three free pills with the first order and then 30% off order number two. 3 Comments [Healthcare]
- Monday, May 6, 9:23 AM Pfizer (PFE) plans to start selling Viagra online, according to an AP report. The initiative could serve as a test run by Big Pharma over disrupting its current model to look at online distribution for treatments viewed as more embarrassing to buy in person. Drugstore operators (CVS, WAG, RAD) will be watching the development very carefully. PFE -0.1% premarket. 2 Comments [Healthcare, Consumer]
- Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
- Tuesday, April 30, 7:21 AM More on Pfizer (PFE) Q1 earnings: Sales fell 9% Y/Y - 8% operational, 1% unfavorable fx adjustment. Much of the operational decrease due to loss of exclusivity of Lipitor. Emerging markets revenue +6%. Adjusted cost of sales fell 7%. FY2013 revenue guidance reduced to $55.3B-$57.3B from $56.2B-$58.2B. Adjusted EPS of $2.14-$2.24 from $2.20-$2.30. About $8B in share repurchases YTD, "with significant additional capital expected to be allocated ... for the remainder of the year." Shares -2.2% premarket. Conference call at 10 ET. (PR) 4 Comments [Healthcare, Earnings, On the Move]
- Tuesday, April 30, 7:01 AM Pfizer (PFE): Q1 EPS of $0.54 misses by $0.01. Revenue of $13.5B misses by $0.6B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 30, 12:05 AM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS Comment! [Earnings]
- Monday, April 29, 5:30 PM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS 1 Comment [Earnings]
- Monday, April 29, 8:18 AM Protalix BioTherapeutics (PLX) rises 6% premarket as its Type I Gaucher disease treatment UPLYSO ("ELELYSO" outside of Latin America) gains approval in Mexico and Chile — it is already approved in the U.S., Israel, and Brazil. The company develops and commercializes the drug with Pfizer (PFE). (PR) Comment! [Healthcare, On the Move]
- Monday, April 29, 7:55 AM Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR) 3 Comments [Healthcare]
- Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
-
- View all 0 replies
-
Joseph P. Porter
Looks like $PFE isn't ready to stay over $30.00 - should think the div would help there. - View all 0 replies
-
- View all 7 replies
-
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
-
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
-
Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling? - View all 3 replies
-
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
-
-
- View all 4 replies
-
-
-
- View all 0 replies
-
Dividend Sheet
$GSK $AEP and $PFE are tomorrow's top ex-dividend stocks - http://stks.co/jUK4 - 2.7% average yield - $UL $PPG $WFC 49 ex-dividend stocks - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 7 replies
-
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
-
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
-
- View all 4 replies
-
-
-
Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling? - View all 3 replies
-
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
-
-
- View all 1 replies
-
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth. -
-
Joseph P. Porter
$PFE pfaithfully pfollows its tradition of offering its divs - $0.24 to be paid in June. Pfar out. - View all 3 replies
-
Joseph P. Porter: Absolutely pfabulous, in my book. Pfizer is to dividends what prunes are to BM's - regularity exemplified. $PFE is pfar and away the best
-
Joseph P. Porter: company I have shares in. So pfar, more than 30% return, not counting divs. Pfortunately, I bought in over a year ago.
-
The Hammer
$PFE breaking out multi-year highs. Lots of investors jumped ship early on this one. It is getting close to oversold. how far does this run? - View all 6 replies
-
The Hammer: Broke above $30 nice. however the pure pharma business model is riskier than the nvs or jnj model more preferred. Hope it runs fast
-
The Hammer: will lighten up into a nice spike from here. reinvested every div over something like 7 years or so.
-
- View all 4 replies
-
Chines33: Only 1 of 2 longs I've had for over a year. Largest position still.
-
bd4uandu: Glad you clarified that in other circles it has other meanings.
-
- View all 2 replies
-
Joseph P. Porter: From Bloomberg - it sounds as if the "correction" could become a Q2-long phenomenon, depending on earnings. They will have to pry $PFE out
-
Joseph P. Porter: of my cold, dead hands. Q2 tends to be a bit iffy, anyway. Much pessimism out there right now because of soft job #'s and Europe.
-
- View all 4 replies
-
-
-
- View all 28 replies
-
Jim Warlick: I've seen a large amount of research on ORCL and largely expect them to achieve 10-15% earnings this year. Watch developing cloud tech. BUY
-
-
- View all 4 replies
-
djamison: I know !!! Just when I was thinking things were are looking good !!
-
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
-
Michael Bryant
"Zoetis's 17 percent sales growth in 2011 outpaced all but Lilly's animal unit..." Wonder how big a stake Pfizer ($PFE) still has. - View all 1 replies
-
-
- View all 6 replies
-
Joseph P. Porter: Whoa! Down > 80% in one sitting. This bears looking into - either something is seriously wrong, or this is one hell of a fine buying opp.
-
Joseph P. Porter: Quick look tells me this is a bargain basement sale. Bought 200 shares $CLSN, will short it.
-
Bob de'Long
If you're new here, click above on Market Currents to see the earnings come in $F $PFE etc. - View all 3 replies
-
Bob de'Long: Valero Energy $VLO) a petroleum refiner Q4 EPS of $1.82 beats by $0.59. Revenue of $34.7B (flat% Y/Y) beats by $3.69B.
-
Bob de'Long: Peabody Energy $BTU): FQ1 EPS of -$1.12. Revenue of $2.01B beats by $0.08B. Stock is down 1% in pre-market